The whole treatment process and thinking of a patient with NUT carcinoma of the parotid gland: a case report

被引：6

作者：

Fu, Shujuan ^{[1
]}

Wang, Zhiying ^{[2
]}

Li, Cunya ^{[1
]}

Li, Yun ^{[1
]}

Zhang, Ke ^{[1
]}

Zhong, Zhixian ^{[3
]}

Zhong, Yi ^{[1
]}

机构：

[1] Shanghai Univ Tradit Chinese Med, Shanghai TCM Intergrated Hosp, Oncol Dept, Shanghai, Peoples R China

[2] Shanghai Univ Tradit Chinese Med, Grad Sch, Shanghai, Peoples R China

[3] Tongji Univ, East Hosp, Sch Med, Breast Canc Ctr, Shanghai, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2023年 / 13卷

关键词：

NUT carcinoma; immunotherapy; targeted therapy; case report; overall survival (OS); MIDLINE CARCINOMA; BEVACIZUMAB; PLUS;

D O I：

10.3389/fonc.2023.1094770

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundPrimary nuclear protein in testis (NUT) carcinoma is a rare malignant tumor originating from the salivary glands that usually occurs in midline structures, such as the head and neck, and has been identified in young patients. Progression of NUT carcinoma is rapid, and there is a high degree of malignant invasion. The median survival time of NUT carcinoma patients is 6 to 9 months, and 80% of the patients die within 1 year after diagnosis. Case descriptionThis case report summarizes the treatment of a 36-year-old male patient with NUT carcinoma of the right parotid gland. The overall survival of the patient was 2 years. We also discuss the applications and outcomes of immune checkpoint inhibitor and targeted therapy combination regimens in the treatment of NUT carcinoma. ConclusionWe suggest that targeted therapy combined with immunotherapy which has long-term clinical benefits and targeted therapy which has high clinical response rate(immunotherapy + dual-targeting three-drug regimens) is an ideal choice for the treatment of patients with rare and/or refractory tumors and will not compromise patient safety.

引用

页数：7

共 22 条

[1] NUT Carcinoma of the Salivary Glands Clinicopathologic and Molecular Analysis of 3 Cases and a Survey of NUT Expression in Salivary Gland Carcinomas [J].

Agaimy, Abbas ;

Fonseca, Isabel ;

Martins, Carmo ;

Thway, Khin ;

Barrette, Ryan ;

Harrington, Kevin J. ;

Hartmann, Arndt ;

French, Christopher A. ;

Fisher, Cyril .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2018, 42 (07) :877-884

[2] Ectopic protein interactions within BRD4-chromatin complexes drive oncogenic megadomain formation in NUT midline carcinoma [J].

Alekseyenko, Artyom A. ;

Walsh, Erica M. ;

Zee, Barry M. ;

Pakozdi, Tibor ;

Hsi, Peter ;

Lemieux, Madeleine E. ;

Dal Cin, Paola ;

Ince, Tan A. ;

Kharchenko, Peter V. ;

Kuroda, Mitzi I. ;

French, Christopher A. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2017, 114 (21) :E4184-E4192

[3] Clinicopathologic Features and Long-term Outcomes of NUT Midline Carcinoma [J].

Bauer, Daniel E. ;

Mitchell, Chelsey M. ;

Strait, Kelly M. ;

Lathan, Christopher S. ;

Stelow, Edward B. ;

Lueer, Sonja C. ;

Muhammed, Somala ;

Evans, Andrew G. ;

Sholl, Lynette M. ;

Rosai, Juan ;

Giraldi, Eugenia ;

Oakley, Richard P. ;

Rodriguez-Galindo, Carlos ;

London, Wendy B. ;

Sallan, Stephen E. ;

Bradner, James E. ;

French, Christopher A. .

CLINICAL CANCER RESEARCH, 2012, 18 (20) :5773-5779

[4] NUT Midline Carcinoma of the Nasal Cavity [J].

Edgar M. ;

Caruso A.M. ;

Kim E. ;

Foss R.D. .

Head and Neck Pathology, 2017, 11 (3) :389-392

[5] Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma [J].

Finn, Richard S. ;

Qin, Shukui ;

Ikeda, Masafumi ;

Galle, Peter R. ;

Ducreux, Michel ;

Kim, Tae-You ;

Kudo, Masatoshi ;

Breder, Valeriy ;

Merle, Philippe ;

Kaseb, Ahmed O. ;

Li, Daneng ;

Verret, Wendy ;

Xu, Derek-Zhen ;

Hernandez, Sairy ;

Liu, Juan ;

Huang, Chen ;

Mulla, Sohail ;

Wang, Yulei ;

Lim, Ho Yeong ;

Zhu, Andrew X. ;

Cheng, Ann-Lii .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (20) :1894-1905

[6] BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells [J].

French, C. A. ;

Ramirez, C. L. ;

Kolmakova, J. ;

Hickman, T. T. ;

Cameron, M. J. ;

Thyne, M. E. ;

Kutok, J. L. ;

Toretsky, J. A. ;

Tadavarthy, A. K. ;

Kees, U. R. ;

Fletcher, J. A. ;

Aster, J. C. .

ONCOGENE, 2008, 27 (15) :2237-2242

[7] The Importance of Diagnosing NUT Midline Carcinoma [J].

French C.A. .

Head and Neck Pathology, 2013, 7 (1) :11-16

[8] Midline carcinoma of children and young adults with NUT rearrangement [J].

French, CA ;

Kutok, JL ;

Faquin, WC ;

Toretsky, JA ;

Antonescu, CR ;

Griffin, CA ;

Nose, V ;

Vargas, SO ;

Moschovi, M ;

Tzortzatou-Stathopoulou, F ;

Miyoshi, I ;

Pcrez-Atayde, AR ;

Aster, JC ;

Fletcher, JA .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (20) :4135-4139

[9] NSD3-NUT Fusion Oncoprotein in NUT Midline Carcinoma: Implications for a Novel Oncogenic Mechanism [J].

French, Christopher A. ;

Rahman, Shaila ;

Walsh, Erica M. ;

Kuehnle, Simone ;

Grayson, Adlai R. ;

Lemieux, Madeleine E. ;

Grunfeld, Noam ;

Rubin, Brian P. ;

Antonescu, Cristina R. ;

Zhang, Songlin ;

Venkatramani, Rajkumar ;

Dal Cin, Paola ;

Howley, Peter M. .

CANCER DISCOVERY, 2014, 4 (08) :928-941

[10] Patterns of care and impact of prognostic factors in the outcome of NUT midline carcinoma: a systematic review and individual patient data analysis of 119 cases [J].

Giridhar, Prashanth ;

Mallick, Supriya ;

Kashyap, Lakhan ;

Rath, Goura Kishor .

EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2018, 275 (03) :815-821

← 1 2 3 →